Third-generation CAR T cell therapy targeting relapsed or refractory CD19+lymphoid disease (HD-CAR-1)

被引:0
|
作者
Schubert, M. -L. [1 ]
Schmitt, A. [1 ]
Neuber, B. [1 ]
Hueckelhoven-Krauss, A. [1 ]
Kunz, A. [1 ]
Wang, L. [1 ]
Gern, U. [1 ]
Michels, B. [1 ]
Sellner, L. [1 ]
Hofmann, S. [1 ]
Mueller-Tidow, C. [1 ]
Dreger, P. [1 ]
Schmitt, M. [1 ]
机构
[1] Univ Klinikum Heidelberg, Med Klin 5, Heidelberg, Germany
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
V840
引用
收藏
页码:236 / 236
页数:1
相关论文
共 50 条
  • [1] CAR T cell therapy targeting relapsed or refractory CD19+lymphoid disease with third-generation vector RV-SFG.CD19.CD28.4-1BBZETA
    Schubert, Maria-Luisa
    Schmitt, Anita
    Sellner, Leopold
    Neuber, Brigitte
    Hueckelhoven-Krauss, Angela
    Alexander, Kunz
    Wang, Lei
    Ulrike, Gern
    Michels, Birgit
    Hofmann, Susanne
    Mueller-Tidow, Carsten
    Peter, Dreger
    Schmitt, Michael
    BONE MARROW TRANSPLANTATION, 2019, 54 : 516 - 517
  • [2] Third-generation chimeric antigen receptor (CAR) T cells in patients with lymphoid disease - results of the Heidelberg trial 1 (HD-CAR-1 trial)
    Schubert, M. L.
    Schmitt, A.
    Neuber, B.
    Hueckelhoven-Krauss, A.
    Kunz, A.
    Wang, L.
    Michels, B.
    Waldhoff, P.
    Sellner, L.
    Korell, F.
    Hofmann, S.
    Pavel, P.
    Ho, A. D.
    Mueller-Tidow, C.
    Dreger, P.
    Schmitt, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 122 - 123
  • [3] Treatment with CD19-directed third-generation chimeric antigen receptor (CAR) T cells - results of the Heidelberg trial 1 (HD-CAR-1 Trial)
    Schubert, M. -L.
    Schmitt, A.
    Neuber, B.
    Hueckelhoven-Krauss, A.
    Kunz, A.
    Wang, L.
    Gern, U.
    Michels, B.
    Hofmann, S.
    Pavel, P.
    Ho, A. D.
    Mueller-Tidow, C.
    Dreger, P.
    Schmitt, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 33 - 34
  • [4] HOME BREWN 3G.CD19.CAR T CELLS FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - (HD-CAR-1)
    Schmitt, M.
    Derigs, P.
    Dreger, P.
    Schmitt, A.
    Schubert, M. -L.
    Kunz, A.
    Mueller-Tidow, C.
    Brueggemann, M.
    Kobbe, G.
    HUMAN GENE THERAPY, 2022, 33 (7-8) : A15 - A16
  • [5] Third-generation CAR T Cells within the Heidelberg CAR Trial 1 (HD-CAR-1) Display an Excellent Safety Profile and Might Improve Persistence of CAR T Cells
    Schubert, Maria-Luisa
    Schmitt, Anita
    Hueckelhoven-Krauss, Angela
    Neuber, Brigitte
    Kunz, Alexander
    Wang, Lei
    Michels, Birgit
    Gern, Ulrike
    Sellner, Leopold
    Hofmann, Susanne
    Pavel, Petra
    Ho, Anthony
    Mueller-Tidow, Carsten
    Dreger, Peter
    Schmitt, Michael
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 46 - 47
  • [6] Third Generation CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed or Refractory Chronic Lymphocytic Leukemia - Update of the Ongoing Academic Phase 1/2 Trial (HD-CAR-1)
    Derigs, P.
    Kunz, A.
    Dreger, P.
    Schmitt, A.
    Schubert, M. -L.
    Bruggemann, M.
    Bernhard, H.
    Kobbe, G.
    Lindemann, A.
    Rummel, M.
    Wang, L.
    Michels, B.
    Waldhoff, P.
    Korell, F.
    Laier, S.
    Ho, A. D.
    Muller-Tidow, C.
    Schmitt, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 41 - 42
  • [7] Treatment of adult all patients with third-generation CD19-directed chimeric antigen receptor (CAR) T cells - results of the Heidelberg Trial 1 (HD-CAR-1 trial)
    Schubert, M. L.
    Schmitt, A.
    Kunz, A.
    Neuber, B.
    Hueckelhoven-Krauss, A.
    Wang, L.
    Michels, B.
    Waldhoff, P.
    Korell, F.
    Derigs, P.
    Haas, D.
    Pavel, P.
    Vonficht, D.
    Haas, S.
    Bug, G.
    Casper, J.
    Goerner, M.
    Finke, J.
    Neubauer, A.
    Ringhoffer, M.
    Ho, A. D.
    Mueller-Tidow, C.
    Dreger, P.
    Schmitt, M.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 27 - 28
  • [8] Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study
    Derigs, Patrick
    Schubert, Maria-Luisa
    Dreger, Peter
    Schmitt, Anita
    Yousefian, Schayan
    Haas, Simon
    Roethemeier, Caroline
    Neuber, Brigitte
    Hueckelhoven-Krauss, Angela
    Brueggemann, Monika
    Bernhard, Helga
    Kobbe, Guido
    Lindemann, Albrecht
    Rummel, Mathias
    Michels, Birgit
    Korell, Felix
    Ho, Anthony D.
    Mueller-Tidow, Carsten
    Schmitt, Michael
    LEUKEMIA, 2024, 38 (11) : 2419 - 2428
  • [9] Treatment of patients with ALL or NHL with third-generation CD19-directed chimeric antigen receptor (CAR) T cells- updated results of the Heidelberg trial 1 (HD-CAR-1 trial)
    Schubert, Maria-Luisa
    Schmitt, Anita
    Haas, Simon
    Derigs, Patrick
    Yousefian, Schayan
    Korell, Felix
    Sauer, Tim
    Ho, Anthony D.
    Mueller-Tidow, Carsten
    Dreger, Peter
    Schmitt, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 147 - 147
  • [10] Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)
    Schubert, Maria-Luisa
    Schmitt, Anita
    Neuber, Brigitte
    Hueckelhoven-Krauss, Angela
    Kunz, Alexander
    Wang, Lei
    Michels, Birgit
    Waldhoff, Philip
    Sellner, Leopold
    Korell, Felix
    Hofmann, Susanne
    Pavel, Petra
    Ho, Anthony D.
    Mueller-Tidow, Carsten
    Dreger, Peter
    Schmitt, Michael
    BLOOD, 2021, 138